TrialBMJ open respiratory research2023

Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial.

John Belperio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.